Granules India Ltd. is an Indian pharmaceutical manufacturing company. Its product range consists of several off-patent drugs, such as ibuprofen, guaifenesin, metformin, and paracetamol. It was incorporated in 1984 with its headquarters in Hyderabad. The company’s quarterly consolidated net sales reported in June 2022 were Rs 1,019.56 crore, up 19.79% from Rs 849.85 crore in June 2021. On 12 August 2022, Granules India Ltd.’s market capitalisation was worth Rs 7,713 crore.
The company is listed on the Bombay Stock Exchange with the code 532482, and on the National Stock Exchange with the code GRANULES. It is also listed on the MCX Stock Exchange, Madras Stock Exchange, and Hyderabad Stock Exchange.
Granules India Ltd.’s product portfolio is diverse, featuring safe, effective, and high-quality drugs. It manufactures active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediaries (PFIs) with complete vertical integration. In the API sector, the company is among the largest manufacturers of first-line of defence products.
On 30 June 2022, Granules India Ltd.’s shareholding pattern indicated a 41.98% promoter stake, 23.13% foreign institutional investor stake, 3.03% domestic institutional investor stake, and 31.85% public stake. Promoters pledged 3.67% shares in the June quarter, making the total pledge of promoter holdings stand at 10.59%. Dr Krishna Prasad Chigurupati was the leading promoter with a 34.8% share. He is the company’s chairman and managing director. During the June 2022 quarter, mutual funds decreased holdings from 3.77% to 3.03%.
The company’s top management comprises Dr K V S Ram Rao, Mrs Uma Devi Chigurupati, Mr Arun Rao Akinepally, Dr Saumen Chakraborty, Mrs Sucharita Rao Palepu, Mr Arun Sawhney, Mr Robert George Cunard, Mr K B Sankar Rao, and Mr Harsha Chigurupati. The auditors are B S R & Associates LLP. On 30 June 2022, the company disclosed a total of 24.80 crore shares outstanding.
Granules India Ltd.’s share price closed at Rs 310.45 on BSE on 12 August 2022. It closed at Rs 310.65 on NSE. The 52-week high for Granules India Ltd.’s share price was Rs 374.70, and the 52-week low for the company’s share price was Rs 227.
The company’s peers include Divis Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., and Glenmark Pharmaceuticals Ltd.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: firstname.lastname@example.org. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose